AlphaStocks
6.3
Consider Buy

EXELIXIS, INC. (EXEL)

Health Care / Biotechnology

S&P MidCap 400

$44.01

Middle of the pack. No strong signal either way.

Consider Buy

Score based on 4 of 5 models — moderate confidence

#217out of 1127 in Health Care

Is EXELIXIS, INC. a Good Investment in 2026?

EXELIXIS, INC. (EXEL) scores 6.3 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Piotroski model rates EXELIXIS, INC. as Strong (7/9). The Graham model is the least favorable, rating it Neutral. EXELIXIS, INC. ranks #217 out of 1127 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E15.8ROE34.8Market Cap12B

Valuation

Trades at 16x earnings — near sector median of 25x.

Fair value estimate not available for this stock.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Strong

7/9

Buffett

Strong

Business quality & competitive moat

Graham

Neutral

87% above fair value

Lynch

Attractive

PEG 1.8 · Stalwart

Greenblatt

Limited Data

Earnings yield + return on capital

Frequently Asked Questions

Is EXELIXIS, INC. (EXEL) a good investment?
Based on AlphaStocks' composite analysis, EXELIXIS, INC. (EXEL) scores 6.3 out of 10, earning a Consider Buy rating. This is a middle-of-the-pack score with no strong signal either way. Trades at 16x earnings — near sector median of 25x.
What is EXELIXIS, INC.'s Piotroski F-Score?
EXELIXIS, INC.'s Piotroski F-Score status is Strong. The raw score is 7/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is EXEL overvalued or undervalued?
A precise fair value estimate is not available for EXEL. Trades at 16x earnings — near sector median of 25x.
How does EXEL compare to other Health Care stocks?
EXELIXIS, INC. ranks #217 out of 1127 stocks in the Health Care sector, placing it in the top 19% of its sector by composite score. This is a strong position relative to sector peers.
What do investment models say about EXEL?
AlphaStocks evaluates EXEL using five proven investment models. Piotroski: Strong; Buffett: Strong; Graham: Neutral; Lynch: Attractive. These models are combined into a single composite score of 6.3/10.

Similar Stocks

PARRFTIAZN

Compare EXEL with

EXEL vs PARREXEL vs FTIEXEL vs AZN

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer